# PARP inhibition in cancer therapy

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/parp-inhibition-in-cancer-therapy-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 663,289 |
| Description | This cluster of papers focuses on the use of Poly(ADP-ribose) Polymerase (PARP) inhibitors, such as Olaparib and Niraparib, as a targeted therapy for cancer, particularly in the context of BRCA mutations and DNA repair deficiency. The concept of synthetic lethality, homologous recombination, and the therapeutic potential of PARP inhibitors in various cancers, including platinum-sensitive ovarian cancer, are extensively explored. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | https://openalex.org/T11914 |
| Works | 42,256 |

## Topic researchers

Showing 12 of 20.

- [Stacey Gabriel](https://scholariq.org/researchers/stacey-gabriel/)
- [Guido Kroemer](https://scholariq.org/researchers/guido-kroemer/)
- [Gad Getz](https://scholariq.org/researchers/gad-getz/)
- [Elaine R. Mardis](https://scholariq.org/researchers/elaine-r-mardis/)
- [John P. A. Ioannidis](https://scholariq.org/researchers/john-p-a-ioannidis/)
- [Matthias Mann](https://scholariq.org/researchers/matthias-mann/)
- [Todd R. Golub](https://scholariq.org/researchers/todd-r-golub/)
- [Matthew Meyerson](https://scholariq.org/researchers/matthew-meyerson/)
- [Chris Sander](https://scholariq.org/researchers/chris-sander/)
- [Gordon B. Mills](https://scholariq.org/researchers/gordon-b-mills/)
- [Piotr Ponikowski](https://scholariq.org/researchers/piotr-ponikowski/)
- [Charles M. Perou](https://scholariq.org/researchers/charles-m-perou/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.